Approval · Notice of Compliance 6299 · 2005
GEN-DIVALPROEX: Notice of Compliance 6299
Issued March 3, 2005
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 6299
- Date
- March 3, 2005
- Company
- Genpharm Inc.Etobicoke, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Anticonvulsant
- Canadian reference product
- EPIVAL (Abbott Laboratories Co.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GEN-DIVALPROEX | 02265133 | Cancelled Post Market |
| GEN-DIVALPROEX | 02265141 | Cancelled Post Market |
| GEN-DIVALPROEX | 02265168 | Cancelled Post Market |
Medicinal ingredients
- DIVALPROEX SODIUM 125 MG per TAB
- DIVALPROEX SODIUM 250 MG per TAB
- DIVALPROEX SODIUM 500 MG per TAB